Literature DB >> 1972549

Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret.

B Costall1, A M Domeney, R J Naylor, J B Owera-Atepo, J A Rudd, F D Tattersall.   

Abstract

The intravenous injection of cisplatin (10 mg/kg), the subcutaneous injection of apomorphine (0.125-1 mg/kg) and lisuride (0.001-0.1 mg/kg), the oral administration of ipecacuanha (0.3-2.4 mg/kg) and the intragastric administration of copper sulphate (25-100 mg/kg), induced a vomiting and retching response in the ferret. Pretreatment with dl-fenfluramine (5 mg/kg i.p.) prevented or reduced the emesis induced by cisplatin, apomorphine, ipecacuanha and lisuride but failed to significantly antagonise copper sulphate-induced emesis. The 5-HT3 receptor antagonist ICS 205-930 (0.1 mg/kg i.p.) prevented emesis induced by cisplatin and ipecacuanha but failed to prevent or significantly reduce the emesis induced by apomorphine, lisuride or copper sulphate. Dopamine receptor antagonists, including fluphenazine (0.1-1.0 mg/kg i.p.) prevented apomorphine- and lisuride-induced emesis but were less potent or had inconsistent actions to antagonise cisplatin- or ipecacuanha-induced emesis and failed to inhibit the emesis induced by copper sulphate. The data indicate that dopamine and/or 5-HT3 receptor systems are involved in drug-induced emesis but that emesis caused by gastric irritation induced by copper sulphate is mediated by different receptor mechanisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972549     DOI: 10.1016/0028-3908(90)90167-p

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  11 in total

1.  The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.

Authors:  T Yoshikawa; N Yoshida; M Oka
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

3.  Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret.

Authors:  Kelvin K W Kan; Man P Ngan; Man K Wai; John A Rudd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-11       Impact factor: 3.000

Review 4.  Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

Authors:  C Veyrat-Follet; R Farinotti; J L Palmer
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

5.  The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor.

Authors:  J W Watson; S F Gonsalves; A A Fossa; S McLean; T Seeger; S Obach; P L Andrews
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

Review 6.  Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic.

Authors:  C R Lee; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 7.  Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.

Authors:  N A Minton
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

Review 8.  Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonists.

Authors:  N Percie du Sert; J A Rudd; C C Apfel; P L R Andrews
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-28       Impact factor: 3.333

9.  Why can't rodents vomit? A comparative behavioral, anatomical, and physiological study.

Authors:  Charles C Horn; Bruce A Kimball; Hong Wang; James Kaus; Samuel Dienel; Allysa Nagy; Gordon R Gathright; Bill J Yates; Paul L R Andrews
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

Review 10.  The involvement of TRPV1 in emesis and anti-emesis.

Authors:  John A Rudd; Eugene Nalivaiko; Norio Matsuki; Christina Wan; Paul Lr Andrews
Journal:  Temperature (Austin)       Date:  2015-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.